A single-center, randomized, double-blind, placebo-controlled single ascending dose and multiple ascending dose study aimed to evaluate the safety, tolerability and pharmacokinetic characteristics of oral HS-10366 in healthy Chinese adults.
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Ibrexafungerp (Primary)
- Indications Candidiasis; Invasive bronchopulmonary aspergillosis; Invasive candidiasis; Mycoses; Vulvovaginal candidiasis
- Focus Adverse reactions
Most Recent Events
- 09 Feb 2024 New trial record